Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P4W | ISIN: SE0023261532 | Ticker-Symbol: PGO0
Frankfurt
08.09.25 | 15:29
0,039 Euro
+0,52 % +0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PROSTATYPE GENOMICS AB Chart 1 Jahr
5-Tage-Chart
PROSTATYPE GENOMICS AB 5-Tage-Chart

Aktuelle News zur PROSTATYPE GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.08.Prostatype Genomics AB: Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype to insurance companies in the USA67Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype®...
► Artikel lesen
23.07.Prostatype Genomics AB: Prostatype Genomics publishes its interim report for the first half of 2025130Prostatype Genomics AB today publishes its interim report for the first half of 2025. The full interim report is attached and can also be downloaded from the company's website, www.prostatypegenomics.com. First...
► Artikel lesen
22.07.Prostatype Genomics AB: Positive results for Prostatype confirmed in published Spanish multicentre study397Prostatype Genomics announces that previously communicated positive results from a Spanish multicentre study with Prostatype®, have now been confirmed in a scientific journal. The study included 93...
► Artikel lesen
PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln
03.06.Prostatype Genomics AB: Strong results for Prostatype in published Taiwan study - creating opportunities for commercial expansion in Asia133Prostatype Genomics announces that strong results from a study in Taiwan with the company's prognostic genomic test Prostatype® have now been published in the scientific journal BJUI Compass. In the...
► Artikel lesen
15.05.Prostatype Genomics AB: Prostatype Genomics updates on commercial progress in the U.S.216Prostatype Genomics announces that the company's commercial activities in the U.S. continue to develop in a positive way. The number of selected American urologists at urology clinics/hospitals who...
► Artikel lesen
15.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2025798Das Instrument B8D CH1107979838 R+S GROUP HOLDI CUM.PREF. EQUITY wird cum Kapitalmassnahme gehandelt am 15.05.2025 und ex Kapitalmassnahme am 16.05.2025 The instrument B8D CH1107979838 R+S GROUP HOLDI...
► Artikel lesen
15.04.Prostatype Genomics AB: Prostatype Genomics AB resolves on a rights issue of units to fund completion of US validation study and Medicare approval process as well as ongoing commercialization activities in the US and Europe184NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA...
► Artikel lesen
10.04.Prostatype Genomics AB: Prostatype Genomics newsletter highlights positive U.S. study results and increasing clinical use in Italy391This newsletter highlights two significant achievements: positive preliminary results in the U.S. study with Prostatype® conducted with leading U.S. institutions, and that the clinical use of Prostatype®...
► Artikel lesen
14.02.Prostatype Genomics AB receives observation status308On February 13, 2025, Prostatype Genomics AB (the "Company") disclosed its annual financial statement release for 2024 with information on the Company's financial situation. The rules of Nasdaq...
► Artikel lesen
13.02.Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2024329Prostatype Genomics AB today publishes its year-end report for the full year 2024, including the interim report for the second half of 2024. The full year-end report is attached and can also be downloaded...
► Artikel lesen
13.02.Prostatype Genomics AB: Prostatype Genomics submits supplementary answers in the final phase of its Medicare application for reimbursement in the United States195Prostatype Genomics AB announces that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype® approved...
► Artikel lesen
31.10.24XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 31.10.2024912The following instruments on XETRA do have their first trading 31.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.10.2024 Aktien 1 HK1126010854 Dream International...
► Artikel lesen
30.10.24XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.10.2024942The following instruments on Boerse Frankfurt do have their last trading day on 30.10.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.10.2024.ISIN NameAU0000282840...
► Artikel lesen
30.10.24XFRA ISIN CHANGE746Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenFR001400JAP8 Acheter-Louer.fr S.A. 30.10.2024 FR001400SOY2 Acheter-Louer.fr S.A. 31.10.2024 Tausch 10000:1SE0014684569...
► Artikel lesen
30.10.24Nasdaq Stockholm AB: Reverse Split and Change of ISIN for Prostatype Genomics AB372Referring to the bulletin from Prostatype Genomics AB's extraordinary general meeting, held on October 22, 2024, the company will carry out a reverse stock split in relations 1:1000. The share will...
► Artikel lesen
28.10.24Prostatype Genomics AB: Prostatype Genomics presents business plan for US market valued at 6 billion SEK (600 million USD) per year286Today, Prostatype Genomics AB presents its business plan for the company's gene test Prostatype® in the US market. In 2025, the goal is to forcefully strengthen and make visible the company's underlying...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1